SACUBITRIL AND VALSARTAN vs VALSARTAN AND HYDROCHLOROTHIAZIDE

Compare SACUBITRIL AND VALSARTAN (ARB) and VALSARTAN AND HYDROCHLOROTHIAZIDE (Valsartan and Hydrochlorothiazide) — clinical data, side effects, and patient experiences.

SACUBITRIL AND VALSARTAN

· ARB

How it works

12.1 Mechanism of Action ENTRESTO contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. ENTRESTO inhibits neprilysin (neutral endopeptidase; ...

Approved for

1 INDICATIONS AND USAGE ENTRESTO is a combination of sacubitril

a neprilisin inhibitor

and valsartan

an angiotensin II receptor blocker

OralTablet

VALSARTAN AND HYDROCHLOROTHIAZIDE

Valsartan and Hydrochlorothiazide · ARB

How it works

12.1 Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pr...

Approved for

1 INDICATIONS AND USAGE Valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension

to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events

primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes

including

OralTablet

Quick Comparison

SACUBITRIL AND VALSARTANVALSARTAN AND HYDROCHLOROTHIAZIDE

Drug Class

ARB

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SACUBITRIL AND VALSARTAN

Low Blood Pressure

>10%

Shortness of Breath

1-10%

Fatigue

1-10%

Cough

1-10%

Weight Loss

1-10%

General Unwellness

0.1-1%

Weight Gain

0.1-1%

Dizziness

1-10%

VALSARTAN AND HYDROCHLOROTHIAZIDE

Fatigue

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

Low Blood Pressure

1-10%

Cough

1-10%

Drug Not Working

1-10%

General Unwellness

1-10%

Weight Loss

1-10%

FDA Warnings

SACUBITRIL AND VALSARTAN

5 WARNINGS AND PRECAUTIONS Observe for signs and symptoms of angioedema and hypotension
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death
However, if there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system, and if the drug is considered lifesaving for the mother, advise a pregnant woman of the potential risk to the fetus [see Use in Specific Populations (8
Angioedema associated with laryngeal edema may be fatal

VALSARTAN AND HYDROCHLOROTHIAZIDE

5 WARNINGS AND PRECAUTIONS Hypotension: Correct volume depletion prior to initiation
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death
Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death
, patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure on valsartan and hydrochlorothiazide

Clinical Trial Data

No head-to-head clinical studies found for SACUBITRIL AND VALSARTAN vs VALSARTAN AND HYDROCHLOROTHIAZIDE.

SACUBITRIL AND VALSARTAN vs VALSARTAN AND HYDROCHLOROTHIAZIDE: What You Should Know

Key Differences

Both SACUBITRIL AND VALSARTAN and VALSARTAN AND HYDROCHLOROTHIAZIDE belong to the ARB class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

SACUBITRIL AND VALSARTAN carries 4 FDA warnings. VALSARTAN AND HYDROCHLOROTHIAZIDE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

SACUBITRIL AND VALSARTAN vs VALSARTAN→IRBESARTAN vs SACUBITRIL AND VALSARTAN→SACUBITRIL AND VALSARTAN vs TELMISARTAN→SACUBITRIL AND VALSARTAN vs TELMISARTAN AND HYDROCHLOROTHIAZIDE→IRBESARTAN AND HYDROCHLOROTHIAZIDE vs SACUBITRIL AND VALSARTAN→SACUBITRIL AND VALSARTAN vs TELMISARTAN AND AMLODIPINE→

Loading comparison data...

SACUBITRIL AND VALSARTAN vs VALSARTAN AND HYDROCHLOROTHIAZIDE

Compare SACUBITRIL AND VALSARTAN (ARB) and VALSARTAN AND HYDROCHLOROTHIAZIDE (Valsartan and Hydrochlorothiazide) — clinical data, side effects, and patient experiences.

SACUBITRIL AND VALSARTAN

· ARB

How it works

12.1 Mechanism of Action ENTRESTO contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. ENTRESTO inhibits neprilysin (neutral endopeptidase; ...

Approved for

1 INDICATIONS AND USAGE ENTRESTO is a combination of sacubitril

a neprilisin inhibitor

and valsartan

an angiotensin II receptor blocker

OralTablet

VALSARTAN AND HYDROCHLOROTHIAZIDE

Valsartan and Hydrochlorothiazide · ARB

How it works

12.1 Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pr...

Approved for

1 INDICATIONS AND USAGE Valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension

to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events

primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes

including

OralTablet

Quick Comparison

SACUBITRIL AND VALSARTANVALSARTAN AND HYDROCHLOROTHIAZIDE

Drug Class

ARB

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SACUBITRIL AND VALSARTAN

Low Blood Pressure

>10%

Shortness of Breath

1-10%

Fatigue

1-10%

Cough

1-10%

Weight Loss

1-10%

General Unwellness

0.1-1%

Weight Gain

0.1-1%

Dizziness

1-10%

VALSARTAN AND HYDROCHLOROTHIAZIDE

Fatigue

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

Low Blood Pressure

1-10%

Cough

1-10%

Drug Not Working

1-10%

General Unwellness

1-10%

Weight Loss

1-10%

FDA Warnings

SACUBITRIL AND VALSARTAN

5 WARNINGS AND PRECAUTIONS Observe for signs and symptoms of angioedema and hypotension
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death
However, if there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system, and if the drug is considered lifesaving for the mother, advise a pregnant woman of the potential risk to the fetus [see Use in Specific Populations (8
Angioedema associated with laryngeal edema may be fatal

VALSARTAN AND HYDROCHLOROTHIAZIDE

5 WARNINGS AND PRECAUTIONS Hypotension: Correct volume depletion prior to initiation
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death
Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death
, patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure on valsartan and hydrochlorothiazide

Clinical Trial Data

No head-to-head clinical studies found for SACUBITRIL AND VALSARTAN vs VALSARTAN AND HYDROCHLOROTHIAZIDE.

SACUBITRIL AND VALSARTAN vs VALSARTAN AND HYDROCHLOROTHIAZIDE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.